Echocardiographic assessment of COVID19 sequelae in survivors with elevated cardiac biomarkers.

ABSTRACT:

Aims

We sought to determine, using advanced echocardiography, the prevalence and type of cardiovascular sequelae after COVID19 infection with marked elevation of cardiovascular biomarkers (CVB), and their prognostic implications.

Methods

All patients admitted from March 1st to May 25th, 2020 to a tertiary referral hospital were included. Those with cardiovascular diseases or dead during admission were excluded. Patients with hs-TnI > 45 ng/L, NT-proBNP>300 pg/mL, and D-dimer >8000 ng/mL were matched with COVID controls (three biomarkers within the normal range) based on intensive care requirements and age, and separately analyzed.

Results

From 2025 patients, 80 patients with significantly elevated CVB and 29 controls were finally included. No differences in baseline c

SUBMITTER: Rodenas-Alesina E 

PROVIDER: S-EPMC9050195 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature